# US 2015/0104466 A1 · Cytomegalovirus disintegrin-like peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104466 A1
- Document ID: US20150104466A1
- Status: Published application
- Kind: A1
- Application number: 14/055,299
- Filed: 2013-10-16
- Published: 2015-04-16
- Earliest claimed: 2013-10-16
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Teresa Compton; Adam L. Feire
- Web page: https://patentgrep.com/patent/US20150104466A1

## CPC

- C07K 16/2839: {against the integrin superfamily}
- C07K 16/089: {Cytomegalovirus}
- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C07K 16/2848: {against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell. Therefore, methods and compositions, such as antiviral agents encompassing the conserved gB disintegrin-like domain and antibodies thereto are described. These active agents interfere with the interaction between virions and cellular integrins, thereby inhibiting viral infection of a host cell.

## Claims

### Claim 1

A method of inhibiting viral infection of an animal host cell, the method comprising administering to the host cell an antiviral-effective amount of an active agent selected from the group consisting of a purified, integrin-binding gB disintegin-like peptide and a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the active agent comprises a purified, integrin-binding gB disintegrin-like peptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein the purified, integrin-binding gB disintegrin-like peptide comprises an amino acid consensus sequence RX5-8DLXXFX5C (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.

### Claim 4 (depends on 2)

The method of claim 2, wherein the purified, integrin-binding gB disintegrin-like peptide comprises an amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.

### Claim 5 (depends on 2)

The method of claim 2, wherein the active agent is administered via a route selected from the group consisting of parenterally, orally, subcutaneously, and topically.

### Claim 6 (depends on 1)

The method of claim 1, wherein the active agent comprises a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.

### Claim 7 (depends on 6)

The method of claim 6, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the consensus sequence RX5-8DLXXFX5C (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.

### Claim 8 (depends on 7)

The method of claim 7, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.

### Claim 9 (depends on 7)

The method of claim 7, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising residues 91-111 of glycoprotein B of human cytomegalovirus.

### Claim 10 (depends on 6)

The method of claim 6, wherein the purified antibody inhibits engagement of virions with cellular integrins.

### Claim 11 (depends on 6)

The method of claim 6, wherein the purified antibody inhibits internalization of virus of family Herpesviridae (V.C. 31) into the host cell.

### Claim 12 (depends on 6)

The method of claim 6, wherein the purified antibody inhibits internalization of virus of family Herpesviridae, sub-family Beta herpesvirinae (V.C. 31.2) into the host cell.

### Claim 13 (depends on 6)

The method of claim 6, wherein the purified antibody inhibits internalization of virus of family Herpesviridae, sub-family Beta herpesvirinae, genus Cytomegalovirus (V.C. 31.2.1) into the host cell.

### Claim 14 (depends on 6)

The method of claim 6, wherein a purified monoclonal antibody is administered to the host cell.

### Claim 15 (depends on 6)

The method of claim 6, wherein a purified polyclonal antibody is administered to the host cell.

### Claim 16

A pharmaceutical composition comprising an antiviral-effective amount of an active agent selected from the group consisting of a purified, integrin-binding gB disintegrin-like peptide, wherein the peptide is capable of inhibiting viral internalization into an animal host cell or an antiviral-effective amount and a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the active agent comprises a purified, integrin-binding gB disintegrin-like peptide.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the purified, integrin-binding gB disintegrin-like peptide comprises an amino acid consensus sequence RX5-8DLXXFX5C (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the purified, integrin-binding gB disintegrin-like peptide comprises an amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, further comprising, in combination, a pharmaceutical carrier suitable for an administration a route selected from the group consisting of parenterally, orally, subcutaneously, and topically.

### Claim 21 (depends on 16)

The pharmaceutical composition of claim 16, wherein the active agent comprises a purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the consensus sequence RX5-8DLXXFX5C (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising residues 91-111 of glycoprotein B of human cytomegalovirus.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody inhibits engagement of virions with cellular integrins.

### Claim 26 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody is a monoclonal antibody.

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, wherein the purified antibody is a polyclonal antibody.

### Claim 28

A purified polypeptide comprising SEQ. ID. NOS: 1-5 or an amino acid sequence having at least 80% homology to SEQ. ID. NOS: 1-5.

### Claim 29

A purified antibody that binds specifically to an integrin-binding, gB disintegrin-like peptide.

### Claim 30 (depends on 29)

The purified antibody of claim 29, wherein the antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the consensus sequence RX5-8DLXXFX5C (SEQ. ID. NOS: 1-4) or an amino acid sequence at least 80% homologous thereto.

### Claim 31 (depends on 29)

The purified antibody of claim 29, wherein the antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising the amino acid sequence RVCSMAQGTDLIRFERNIVC (SEQ. ID. NO: 5) or an amino acid sequence at least 80% homologous thereto.

### Claim 32 (depends on 29)

The purified antibody of claim 29, wherein the antibody binds selectively to an integrin-binding, gB disintegrin-like peptide comprising residues 91-111 of glycoprotein B of human cytomegalovirus.

### Claim 33 (depends on 29)

The purified antibody of claim 29, wherein the antibody inhibits engagement of virions with cellular integrins.

### Claim 34 (depends on 29)

The purified antibody of claim 29, wherein the antibody inhibits internalization of virus of family Herpesviridae (V.C. 31) into host cells.

### Claim 35 (depends on 29)

The purified antibody of claim 29, wherein the antibody inhibits internalization of virus of family Herpesviridae, sub-family Beta herpesvirinae (V.C. 31.2) into host cells.

### Claim 36 (depends on 29)

The purified antibody of claim 29, wherein the antibody inhibits internalization of virus of family Herpesviridae, sub-family Beta herpesvirinae, genus Cytomegalovirus (V.C. 31.2.1) into host cells.

### Claim 37 (depends on 29)

The purified antibody of claim 29, wherein the antibody is a monoclonal antibody.

### Claim 38 (depends on 29)

The purified antibody of claim 29, wherein the antibody is a polyclonal antibody.
